• Advancis Pharmaceutical Corp., of Germantown, Md., entered definitive purchase agreements for the private placement of 6 million shares, raising $18 million gross. Pacific Growth Equities LLC acted as lead placement agent, and Susquehanna Financial Group LLLP acted as co-placement agent. The company intends to use the proceeds for the potential commercial launch of Amoxicillin PULSYS, and to continue to develop other products.

• Angiotech Pharmaceuticals Inc., of Vancouver, British Columbia, closed a sale of $325 million in senior floating rate notes due 2013. Net proceeds were used to repay the outstanding amount under the company's senior secured term loan facility.

• Arena Pharmaceuticals Inc., of San Diego, priced about 11.5 million shares of its common stock at $13.21 per share in a public offering. The underwriters have a 30-day option to purchase up to 1.7 million shares to cover overallotments. CIBC World Markets Corp. is acting as sole book-running manager. Cowen and Co. LLC and Piper Jaffray & Co. are acting as co-lead managers. Needham & Co. LLC, Leerink Swann & Co. Inc., Fortis Securities LLC, Morgan Joseph & Co. Inc. and Oppenheimer & Co. Inc. are acting as co-managers.

• Celgene Corp., of Summit, N.J., acquired an active pharmaceutical ingredient (API) manufacturing facility from Siegfried Ltd., a manufacturer of pharmaceutical products located in Zofingen, Switzerland. Celgene is purchasing the assets for about $46.5 million in cash, with an initial payment of $12.5 million. The manufacturing facility initially will be used to produce Revlimid to supply global markets.

• Galapagos NV, of Mechelen, Belgium, and The ALS Association, a Calabasas Hills Calif., a nonprofit health organization dedicated to finding a cure for amyotrophic lateral sclerosis, formed a new two-year target discovery alliance. Galapagos' service division, BioFocus DPI, will apply its adenoviral platform to identify drug targets for the development of new ALS therapies. Galapagos may receive up to €2.4 million (US$3 million) from The ALS Association. In addition, Galapagos has the option to further develop certain targets.

• Medivation Inc., of San Francisco, entered into definitive purchase agreements with institutional investors to sell about 2.2 million shares at $16.25 each in a registered direct offering that will raise $36 million gross. Closing is expected Dec. 13. Cowen and Co. LLC served as the lead placement agent for the offering. Co-placement agents were Leerink Swann & Co., Rodman & Renshaw LLC and Emerging Growth Equities Ltd.

• Symphogen AS, of Copenhagen, Denmark, and Meiji Seika Kaisha Ltd., of Tokyo, entered a research, development and commercialization agreement that uses Symphogen's antibody discovery technology, Symplex, to develop a fully human recombinant polyclonal antibody that targets a nondisclosed bacterial pathogen. Symphogen will receive an initial technology access fee from Meiji and is eligible to receive development milestone payments, as well as royalties on worldwide net sales. Meiji has agreed to fund the development costs associated with the program. Symphogen has retained certain co-development option rights in the United States and European Union.

• TechnoVax Inc., of Tarrytown, N.Y., signed a license agreement with Wyeth, of Madison, N.J., to obtain rights to a fundamental patent application in the field of virus-like particle technology. The agreement provides for an up-front payment, annual minimum royalty payments, milestone payments to Wyeth upon the achievement of certain development events, royalties on product sales and an equity grant to Wyeth when TechnoVax completes an initial equity financing. The patent application is based on viral vaccine research conducted by TechnoVax founder, Jose Galarza, while employed at Wyeth. It is applicable to the preparation of vaccines against a number of potential pandemic organisms.